Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
203 SEK | -2.87% | -0.49% | 0.00% |
04-23 | Transcript : Probi AB, Q1 2024 Earnings Call, Apr 23, 2024 | |
04-23 | Probi AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
Weaknesses
- With an expected P/E ratio at 151.49 and 72.76 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
0.00% | 217M | C+ | ||
+26.47% | 661B | C+ | ||
+26.74% | 566B | B | ||
-6.33% | 352B | C+ | ||
+19.35% | 332B | B- | ||
+4.23% | 283B | C+ | ||
+13.43% | 231B | B+ | ||
+4.71% | 200B | B- | ||
-9.53% | 195B | A+ | ||
-4.04% | 145B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PROB Stock
- Ratings Probi AB